Serina TherapeuticsFRA:2BO +8.03%19 Market Cap is €25.94 Mil as of Jun. 30, 2026. GuruFocus rates FRA:2BO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, Serina Therapeutics ranks worse than 71.85% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Serina Therapeutics's share price for the quarter that ended in Mar. 2026 was €1.62. Serina Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 14.90 Mil. Therefore, Serina Therapeutics's market cap for the quarter that ended in Mar. 2026 was €24.14 Mil.
Serina Therapeutics's quarterly market cap
declined
from Sep. 2025 (€42.80 Mil) to Dec. 2025 (€20.46 Mil) but then
increased
from Dec. 2025 (€20.46 Mil) to Mar. 2026 (€24.14 Mil).
Serina Therapeutics's annual market cap
increased
from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€48.52 Mil) but then
declined
from Dec. 2024 (€48.52 Mil) to Dec. 2025 (€20.46 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Serina Therapeutics's Enterprise Value for Today is €11.53 Mil.
Serina Therapeutics (FRA:2BO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Serina Therapeutics Market Cap Related Terms
Serina Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Serina Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Serina Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Serina Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Serina Therapeutics (FRA:2BO) has a Market Cap of €25.94 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #1026 out of 1428 companies in the Biotechnology industry, placing it in the top 71.8%.
Is Serina Therapeutics' Market Cap too high?
Serina Therapeutics' current Market Cap is €25.94 Mil. Based on the distribution chart, Serina Therapeutics ranks #1026 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Serina Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Market Cap compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #1026 out of 1428 companies for Market Cap. This places Serina Therapeutics in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Serina Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Serina Therapeutics's current Market Cap is €25.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current Market Cap of €25.94 Mil. The current Market Cap is €25.94 Mil. Serina Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current Market Cap is €25.94 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
19GF Score
Get the complete analysis for FRA:2BO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2BO has been successfully added to your 
